Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
09:44am, Wednesday, 03'rd Jun 2026
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
10:10pm, Tuesday, 12'th May 2026
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
05:07am, Saturday, 09'th May 2026
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clini
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
06:01am, Wednesday, 06'th May 2026
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
04:05pm, Tuesday, 05'th May 2026
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and contin
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
04:05pm, Tuesday, 28'th Apr 2026
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalb
Trevi Therapeutics to Participate in Upcoming May Events
04:05pm, Thursday, 23'rd Apr 2026
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral n
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuph
What's Going On With Trevi Therapeutics Stock?
11:41am, Friday, 17'th Apr 2026
Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares are trading higher after the company announced the pricing of its $150 million offering of 11.6 million shares at $13 per share.
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
10:42pm, Thursday, 16'th Apr 2026
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuph
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
04:08pm, Thursday, 16'th Apr 2026
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuph
SG Americas Securities LLC Has $1.56 Million Stock Position in Trevi Therapeutics, Inc. $TRVI
05:05am, Tuesday, 07'th Apr 2026
SG Americas Securities LLC raised its stake in Trevi Therapeutics, Inc. (NASDAQ: TRVI) by 93.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commi
Trevi Therapeutics to Participate in Upcoming Events
07:30am, Wednesday, 01'st Apr 2026
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuph
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts
04:24am, Saturday, 28'th Mar 2026
Trevi Therapeutics, Inc. (NASDAQ: TRVI - Get Free Report) has earned an average recommendation of "Buy" from the twelve ratings firms that are covering the company, MarketBeat.com reports. One investm
